Researchers determined the impact of mutations in the CALR gene on thrombotic risk for patients with essential thrombocythemia.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
A review of 13 cases of MPN in younger patients sought to determine whether pegylated interferon, used to treat adult patients with these diseases, was appropriate for patients younger than 21.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.
For patients with relapsed or refractory multiple myeloma, subcutaneous bortezomib may improve the tolerability of combination panobinostat, bortezomib, and dexamethasone.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.
Several biomarkers were predictive of progression from smoldering MM to MM, according to a retrospective study.
Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.
Among patients with myelodysplastic syndrome, long noncoding RNA KIAA0125 may predict poorer overall survival and leukemia-free survival.
A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
A geno-clinical model used mutational data and peripheral blood counts to accurately distinguish myelodysplastic syndromes from other myeloid malignancies.
Combination therapy positively influenced overall survival rates, dyspnea, and fatigue through 48 weeks in this patient population.
Researchers present data regarding end-of-life care management in patients with multiple myeloma.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.